A 5-Question Quiz on Melanoma

June 8th 2025

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD

June 9th 2025

Ibrilatazar Shows Survival Improvement in Advanced Squamous NSCLC

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Roman Fabbricatore

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD

Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

Experts weigh in on the practical applications of PSMA PET imaging

$Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC$

Tim Cortese

Sacituzumab Tirumotecan Improves Response vs Docetaxel in EFGR+ NSCLC

A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

RP1/Nivolumab Combo Shows Responses in Advanced Pretreated Melanoma

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

Related Content

June 8th 2025

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD

June 9th 2025

Ibrilatazar Shows Survival Improvement in Advanced Squamous NSCLC

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Roman Fabbricatore

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD

Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

Experts weigh in on the practical applications of PSMA PET imaging

$Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC$

Tim Cortese

Sacituzumab Tirumotecan Improves Response vs Docetaxel in EFGR+ NSCLC

A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.